Myocardial Ischemia Induced by 5‐Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study
Background Cardiotoxicity induced by 5‐fluorouracil (5‐FU) is well known but poorly understood. In this study, we undertook ECG recording (Holter) and analyses of the biomarkers troponin and copeptin in patients receiving 5‐FU to increase our understanding of the cardiotoxicity. Subjects, Materials,...
Saved in:
| Published in | The oncologist (Dayton, Ohio) Vol. 26; no. 3; pp. e403 - e413 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Hoboken, USA
John Wiley & Sons, Inc
01.03.2021
Oxford University Press |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1083-7159 1549-490X 1549-490X |
| DOI | 10.1002/onco.13536 |
Cover
| Abstract | Background
Cardiotoxicity induced by 5‐fluorouracil (5‐FU) is well known but poorly understood. In this study, we undertook ECG recording (Holter) and analyses of the biomarkers troponin and copeptin in patients receiving 5‐FU to increase our understanding of the cardiotoxicity.
Subjects, Materials, and Methods
Patients with colorectal or anal cancer that received first‐time treatment with 5‐FU‐based chemotherapy were prospectively included. Holter recording, clinical evaluation, 12‐lead electrocardiogram, and assessment of plasma concentrations of troponin I and copeptin were performed before (control) and during 5‐FU treatment (intervention).
Results
A total of 108 patients were included, 82 with colorectal and 26 with anal cancer. The proportion of patients with myocardial ischemia on Holter recording was significantly higher during the first 5‐FU infusion (14.1%) than before (3.7%; p = .001). The ischemic burden per day (p = .001), the number of ST depression episodes per day (p = .003), and the total duration of ischemic episodes per day (p = .003) were higher during the first 5‐FU infusion than before, as was plasma copeptin (p < .001), whereas plasma troponin I was similar (p > 0.999). Six patients (5.6%) developed acute coronary syndromes and two (1.8%) developed symptomatic arrhythmias during 5‐FU treatment.
Conclusion
5‐FU infusion is associated with an increase in the number of patients with myocardial ischemia on Holter recording. According to biomarker analyses, 5‐FU is associated with an increase in copeptin, but rarely with increases in cardiac troponin I. However, 5%–6% of the patients developed acute coronary syndromes during treatment with 5‐FU.
Implications for Practice
Symptomatic 5‐fluorouracil (5‐FU) cardiotoxicity occurs in 0.6%–19% of patients treated with this drug, but a small electrocardiographic (Holter) study has revealed silent myocardial ischemia in asymptomatic patients, suggesting a more prevalent subclinical cardiac influence. This study demonstrated a significant increase in the number of patients with myocardial ischemia on Holter recording during 5‐FU treatment and an increase in ischemic burden. Cardiac biomarker analyses suggested that 5‐FU infusion results in endogenous stress (increased copeptin) but rarely induces myocyte injury (no change in troponin). These findings suggest a more prevalent cardiac influence from 5‐FU and that Holter recording is an important tool in the evaluation of patients with suspected cardiotoxicity from 5‐FU.
Cardiotoxicity related to 5‐fluorouracil (5‐FU) treatment is poorly understood. This article reports results of a study using electrocardiogram results to analyze the biomarkers troponin and copeptin in patients receiving 5‐FU. |
|---|---|
| AbstractList | Cardiotoxicity induced by 5-fluorouracil (5-FU) is well known but poorly understood. In this study, we undertook ECG recording (Holter) and analyses of the biomarkers troponin and copeptin in patients receiving 5-FU to increase our understanding of the cardiotoxicity.BACKGROUNDCardiotoxicity induced by 5-fluorouracil (5-FU) is well known but poorly understood. In this study, we undertook ECG recording (Holter) and analyses of the biomarkers troponin and copeptin in patients receiving 5-FU to increase our understanding of the cardiotoxicity.Patients with colorectal or anal cancer that received first-time treatment with 5-FU-based chemotherapy were prospectively included. Holter recording, clinical evaluation, 12-lead electrocardiogram, and assessment of plasma concentrations of troponin I and copeptin were performed before (control) and during 5-FU treatment (intervention).SUBJECTS, MATERIALS, AND METHODSPatients with colorectal or anal cancer that received first-time treatment with 5-FU-based chemotherapy were prospectively included. Holter recording, clinical evaluation, 12-lead electrocardiogram, and assessment of plasma concentrations of troponin I and copeptin were performed before (control) and during 5-FU treatment (intervention).A total of 108 patients were included, 82 with colorectal and 26 with anal cancer. The proportion of patients with myocardial ischemia on Holter recording was significantly higher during the first 5-FU infusion (14.1%) than before (3.7%; p = .001). The ischemic burden per day (p = .001), the number of ST depression episodes per day (p = .003), and the total duration of ischemic episodes per day (p = .003) were higher during the first 5-FU infusion than before, as was plasma copeptin (p < .001), whereas plasma troponin I was similar (p > 0.999). Six patients (5.6%) developed acute coronary syndromes and two (1.8%) developed symptomatic arrhythmias during 5-FU treatment.RESULTSA total of 108 patients were included, 82 with colorectal and 26 with anal cancer. The proportion of patients with myocardial ischemia on Holter recording was significantly higher during the first 5-FU infusion (14.1%) than before (3.7%; p = .001). The ischemic burden per day (p = .001), the number of ST depression episodes per day (p = .003), and the total duration of ischemic episodes per day (p = .003) were higher during the first 5-FU infusion than before, as was plasma copeptin (p < .001), whereas plasma troponin I was similar (p > 0.999). Six patients (5.6%) developed acute coronary syndromes and two (1.8%) developed symptomatic arrhythmias during 5-FU treatment.5-FU infusion is associated with an increase in the number of patients with myocardial ischemia on Holter recording. According to biomarker analyses, 5-FU is associated with an increase in copeptin, but rarely with increases in cardiac troponin I. However, 5%-6% of the patients developed acute coronary syndromes during treatment with 5-FU.CONCLUSION5-FU infusion is associated with an increase in the number of patients with myocardial ischemia on Holter recording. According to biomarker analyses, 5-FU is associated with an increase in copeptin, but rarely with increases in cardiac troponin I. However, 5%-6% of the patients developed acute coronary syndromes during treatment with 5-FU.Symptomatic 5-fluorouracil (5-FU) cardiotoxicity occurs in 0.6%-19% of patients treated with this drug, but a small electrocardiographic (Holter) study has revealed silent myocardial ischemia in asymptomatic patients, suggesting a more prevalent subclinical cardiac influence. This study demonstrated a significant increase in the number of patients with myocardial ischemia on Holter recording during 5-FU treatment and an increase in ischemic burden. Cardiac biomarker analyses suggested that 5-FU infusion results in endogenous stress (increased copeptin) but rarely induces myocyte injury (no change in troponin). These findings suggest a more prevalent cardiac influence from 5-FU and that Holter recording is an important tool in the evaluation of patients with suspected cardiotoxicity from 5-FU.IMPLICATIONS FOR PRACTICESymptomatic 5-fluorouracil (5-FU) cardiotoxicity occurs in 0.6%-19% of patients treated with this drug, but a small electrocardiographic (Holter) study has revealed silent myocardial ischemia in asymptomatic patients, suggesting a more prevalent subclinical cardiac influence. This study demonstrated a significant increase in the number of patients with myocardial ischemia on Holter recording during 5-FU treatment and an increase in ischemic burden. Cardiac biomarker analyses suggested that 5-FU infusion results in endogenous stress (increased copeptin) but rarely induces myocyte injury (no change in troponin). These findings suggest a more prevalent cardiac influence from 5-FU and that Holter recording is an important tool in the evaluation of patients with suspected cardiotoxicity from 5-FU. Subjects, Materials, and Methods. Patients with colorectal or anal cancer that received first-time treatment with 5-FUbased chemotherapy were prospectively included. Holter recording, clinical evaluation, 12-lead electrocardiogram, and assessment of plasma concentrations of troponin I and copeptin were performed before (control) and during 5-FU treatment (intervention). Cardiotoxicity related to 5‐fluorouracil (5‐FU) treatment is poorly understood. This article reports results of a study using electrocardiogram results to analyze the biomarkers troponin and copeptin in patients receiving 5‐FU. Cardiotoxicity induced by 5-fluorouracil (5-FU) is well known but poorly understood. In this study, we undertook ECG recording (Holter) and analyses of the biomarkers troponin and copeptin in patients receiving 5-FU to increase our understanding of the cardiotoxicity. Patients with colorectal or anal cancer that received first-time treatment with 5-FU-based chemotherapy were prospectively included. Holter recording, clinical evaluation, 12-lead electrocardiogram, and assessment of plasma concentrations of troponin I and copeptin were performed before (control) and during 5-FU treatment (intervention). A total of 108 patients were included, 82 with colorectal and 26 with anal cancer. The proportion of patients with myocardial ischemia on Holter recording was significantly higher during the first 5-FU infusion (14.1%) than before (3.7%; p = .001). The ischemic burden per day (p = .001), the number of ST depression episodes per day (p = .003), and the total duration of ischemic episodes per day (p = .003) were higher during the first 5-FU infusion than before, as was plasma copeptin (p < .001), whereas plasma troponin I was similar (p > 0.999). Six patients (5.6%) developed acute coronary syndromes and two (1.8%) developed symptomatic arrhythmias during 5-FU treatment. 5-FU infusion is associated with an increase in the number of patients with myocardial ischemia on Holter recording. According to biomarker analyses, 5-FU is associated with an increase in copeptin, but rarely with increases in cardiac troponin I. However, 5%-6% of the patients developed acute coronary syndromes during treatment with 5-FU. Symptomatic 5-fluorouracil (5-FU) cardiotoxicity occurs in 0.6%-19% of patients treated with this drug, but a small electrocardiographic (Holter) study has revealed silent myocardial ischemia in asymptomatic patients, suggesting a more prevalent subclinical cardiac influence. This study demonstrated a significant increase in the number of patients with myocardial ischemia on Holter recording during 5-FU treatment and an increase in ischemic burden. Cardiac biomarker analyses suggested that 5-FU infusion results in endogenous stress (increased copeptin) but rarely induces myocyte injury (no change in troponin). These findings suggest a more prevalent cardiac influence from 5-FU and that Holter recording is an important tool in the evaluation of patients with suspected cardiotoxicity from 5-FU. Background Cardiotoxicity induced by 5‐fluorouracil (5‐FU) is well known but poorly understood. In this study, we undertook ECG recording (Holter) and analyses of the biomarkers troponin and copeptin in patients receiving 5‐FU to increase our understanding of the cardiotoxicity. Subjects, Materials, and Methods Patients with colorectal or anal cancer that received first‐time treatment with 5‐FU‐based chemotherapy were prospectively included. Holter recording, clinical evaluation, 12‐lead electrocardiogram, and assessment of plasma concentrations of troponin I and copeptin were performed before (control) and during 5‐FU treatment (intervention). Results A total of 108 patients were included, 82 with colorectal and 26 with anal cancer. The proportion of patients with myocardial ischemia on Holter recording was significantly higher during the first 5‐FU infusion (14.1%) than before (3.7%; p = .001). The ischemic burden per day (p = .001), the number of ST depression episodes per day (p = .003), and the total duration of ischemic episodes per day (p = .003) were higher during the first 5‐FU infusion than before, as was plasma copeptin (p < .001), whereas plasma troponin I was similar (p > 0.999). Six patients (5.6%) developed acute coronary syndromes and two (1.8%) developed symptomatic arrhythmias during 5‐FU treatment. Conclusion 5‐FU infusion is associated with an increase in the number of patients with myocardial ischemia on Holter recording. According to biomarker analyses, 5‐FU is associated with an increase in copeptin, but rarely with increases in cardiac troponin I. However, 5%–6% of the patients developed acute coronary syndromes during treatment with 5‐FU. Implications for Practice Symptomatic 5‐fluorouracil (5‐FU) cardiotoxicity occurs in 0.6%–19% of patients treated with this drug, but a small electrocardiographic (Holter) study has revealed silent myocardial ischemia in asymptomatic patients, suggesting a more prevalent subclinical cardiac influence. This study demonstrated a significant increase in the number of patients with myocardial ischemia on Holter recording during 5‐FU treatment and an increase in ischemic burden. Cardiac biomarker analyses suggested that 5‐FU infusion results in endogenous stress (increased copeptin) but rarely induces myocyte injury (no change in troponin). These findings suggest a more prevalent cardiac influence from 5‐FU and that Holter recording is an important tool in the evaluation of patients with suspected cardiotoxicity from 5‐FU. Cardiotoxicity related to 5‐fluorouracil (5‐FU) treatment is poorly understood. This article reports results of a study using electrocardiogram results to analyze the biomarkers troponin and copeptin in patients receiving 5‐FU. Background. Cardiotoxicity induced by 5-fluorouracil (5-FU) is well known but poorly understood. In this study, we undertook ECG recording (Holter) and analyses of the biomarkers troponin and copeptin in patients receiving 5-FU to increase our understanding of the cardiotoxicity. Subjects, Materials, and Methods. Patients with colorectal or anal cancer that received first-time treatment with 5-FUbased chemotherapy were prospectively included. Holter recording, clinical evaluation, 12-lead electrocardiogram, and assessment of plasma concentrations of troponin I and copeptin were performed before (control) and during 5-FU treatment (intervention). Results. A total of 108 patients were included, 82 with colorectal and 26 with anal cancer. The proportion of patients with myocardial ischemia on Holter recording was significantly higher during the first 5-FU infusion (14.1%) than before (3.7%; p = .001). The ischemic burden per day (p = .001), the number of ST depression episodes per day (p = .003), and the total duration of ischemic episodes per day (p = .003) were higher during the first 5-FU infusion than before, as was plasma copeptin (p < .001), whereas plasma troponin I was similar (p > 0.999). Six patients (5.6%) developed acute coronary syndromes and two (1.8%) developed symptomatic arrhythmias during 5-FU treatment. Conclusion. 5-FU infusion is associated with an increase in the number of patients with myocardial ischemia on Holter recording. According to biomarker analyses, 5-FU is associated with an increase in copeptin, but rarely with increases in cardiac troponin I. However, 5%-6% of the patients developed acute coronary syndromes during treatment with 5-FU. The Oncologist 2021;26:e403-e413 Key Words. 5-Flourouracil * Cardiotoxicity * Myocardial ischemia * Colorectal cancer * Anal cancer |
| Audience | Professional Academic |
| Author | Bojesen, Stig E. Dyhl‐Polk, Anne Nielsen, Dorte L. Klausen, Tobias W. Serup‐Hansen, Eva Schou, Morten Vaage‐Nilsen, Merete Vistisen, Kirsten K. Sillesen, Anne‐Sophie Faber, Jens |
| AuthorAffiliation | 3 Departments of Medicine, Herlev‐Gentofte Hospital, University of Copenhagen Herlev Denmark 1 Departments of Oncology, Herlev‐Gentofte Hospital, University of Copenhagen Herlev Denmark 6 Faculty of Health and Medical Sciences, University of Copenhagen Copenhagen Denmark 5 Departments of Clinical Biochemistry, Herlev‐Gentofte Hospital, University of Copenhagen Herlev Denmark 4 Departments of Hematology, Herlev‐Gentofte Hospital, University of Copenhagen Herlev Denmark 2 Departments of Cardiology, Herlev‐Gentofte Hospital, University of Copenhagen Herlev Denmark |
| AuthorAffiliation_xml | – name: 2 Departments of Cardiology, Herlev‐Gentofte Hospital, University of Copenhagen Herlev Denmark – name: 4 Departments of Hematology, Herlev‐Gentofte Hospital, University of Copenhagen Herlev Denmark – name: 3 Departments of Medicine, Herlev‐Gentofte Hospital, University of Copenhagen Herlev Denmark – name: 6 Faculty of Health and Medical Sciences, University of Copenhagen Copenhagen Denmark – name: 1 Departments of Oncology, Herlev‐Gentofte Hospital, University of Copenhagen Herlev Denmark – name: 5 Departments of Clinical Biochemistry, Herlev‐Gentofte Hospital, University of Copenhagen Herlev Denmark |
| Author_xml | – sequence: 1 givenname: Anne orcidid: 0000-0003-2335-8219 surname: Dyhl‐Polk fullname: Dyhl‐Polk, Anne email: anne.polk@hotmail.com organization: Faculty of Health and Medical Sciences, University of Copenhagen – sequence: 2 givenname: Morten surname: Schou fullname: Schou, Morten organization: Faculty of Health and Medical Sciences, University of Copenhagen – sequence: 3 givenname: Kirsten K. surname: Vistisen fullname: Vistisen, Kirsten K. organization: Departments of Oncology, Herlev‐Gentofte Hospital, University of Copenhagen – sequence: 4 givenname: Anne‐Sophie surname: Sillesen fullname: Sillesen, Anne‐Sophie organization: Departments of Cardiology, Herlev‐Gentofte Hospital, University of Copenhagen – sequence: 5 givenname: Eva surname: Serup‐Hansen fullname: Serup‐Hansen, Eva organization: Departments of Oncology, Herlev‐Gentofte Hospital, University of Copenhagen – sequence: 6 givenname: Jens surname: Faber fullname: Faber, Jens organization: Faculty of Health and Medical Sciences, University of Copenhagen – sequence: 7 givenname: Tobias W. surname: Klausen fullname: Klausen, Tobias W. organization: Departments of Hematology, Herlev‐Gentofte Hospital, University of Copenhagen – sequence: 8 givenname: Stig E. surname: Bojesen fullname: Bojesen, Stig E. organization: Faculty of Health and Medical Sciences, University of Copenhagen – sequence: 9 givenname: Merete surname: Vaage‐Nilsen fullname: Vaage‐Nilsen, Merete organization: Departments of Cardiology, Herlev‐Gentofte Hospital, University of Copenhagen – sequence: 10 givenname: Dorte L. surname: Nielsen fullname: Nielsen, Dorte L. organization: Faculty of Health and Medical Sciences, University of Copenhagen |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32959474$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks2KFDEQx4OsuB968QEk4EWEHvM5nXhYGIddHVgdQQVvIZ2kZ6KZzpjuXumbj-Az-iSmt3fFlUVySFH5_f9UpeoYHDSxcQA8xmiGESIvYmPiDFNO5_fAEeZMFkyizwc5RoIWJebyEBy37ReEckjJA3BIieSSlewIxLdDNDpZrwNctWbrdl7DVWN74yysBsh__fh5HvqYYp-08eElXMD3KbZ7Zzp_6eBZyEGaLOIm6f3WG6gbC5dXpga-8nGn01eX4Ieut8NDcL_WoXWPru8T8On87OPyTXGxfr1aLi4KwxCZF7QW2GKMTCUptQQbSkTNhCtrzPlcc8ldZRlydVkTazipGLOGEY2dlILMBT0Bp5Pvvq92zhrXdEkHtU8-VzOoqL26_dL4rdrES1VKihgh2eDZtUGK33rXdmrnW-NC0I2LfasIY0wITPGIPp3QjQ5O-aaO2dGMuFqUAmGKBBqp2R1UPjb_uckTrX3O3xI8-buFP7XfDC8DaAJMHkibXK2M73Tn49iRDwojNe6HGvdDXe1Hljz_R3LjeieMJ_h7rmz4D6nW75brSfMbTZvMZw |
| CitedBy_id | crossref_primary_10_1016_j_esmoop_2022_100427 crossref_primary_10_1093_oncolo_oyab035 crossref_primary_10_4251_wjgo_v16_i2_251 crossref_primary_10_1007_s11912_022_01256_6 crossref_primary_10_3389_fcvm_2022_960240 crossref_primary_10_3390_ph16040510 crossref_primary_10_1016_j_cpcardiol_2022_101435 crossref_primary_10_3390_cancers16020385 crossref_primary_10_1007_s00761_021_00929_4 crossref_primary_10_3390_cimb47030176 crossref_primary_10_1016_j_esmoop_2023_101199 crossref_primary_10_3390_biom13020321 crossref_primary_10_4274_balkanmedj_galenos_2023_2023_2_14 crossref_primary_10_3389_fcvm_2022_991886 crossref_primary_10_3389_fphar_2022_885699 crossref_primary_10_1007_s12012_024_09834_9 crossref_primary_10_3390_ph16091312 |
| Cites_doi | 10.1161/01.CIR.78.1.60 10.1016/j.ijcard.2012.12.039 10.1016/j.amjcard.2011.06.058 10.1016/S0002-9149(99)00526-3 10.1161/01.CIR.0000088001.59265.EE 10.15420/ahhj.2010.8.2.111 10.1093/annonc/mdu055 10.1093/annonc/mdw235 10.1016/j.clcc.2018.09.006 10.1111/j.0742-2822.2005.03169.x 10.1517/14740330902733961 10.1016/0735-1097(94)90503-7 10.1007/s00392-011-0343-y 10.1177/107327480401100107 10.1373/clinchem.2016.255109 10.1093/jjco/hyh047 10.4172/2161-0495.1000211 10.1016/j.tem.2007.11.001 10.1093/eurheartj/ehv320 10.1016/j.jacc.2008.04.033 10.1200/JCO.2020.38.15_suppl.7037 10.1592/phco.31.2.226 10.1177/0003319716637516 10.1136/hrt.76.6.477 10.1111/j.1742-1241.2007.01323.x 10.1016/j.ctrv.2013.03.005 10.1111/j.1751-7133.2010.00177.x 10.1016/0002-9149(94)90551-7 10.1093/oxfordjournals.eurheartj.a059919 10.1046/j.1542-474X.2003.08306.x 10.1097/01.hjr.0000176511.22284.c1 10.1016/j.pcad.2013.07.001 10.1177/1758835918780140 10.1200/JCO.1997.15.2.808 10.1007/s12032-009-9226-8 10.1016/j.amjcard.2014.01.436 10.1093/gerona/57.3.M178 10.1016/j.ejca.2017.05.022 10.1023/A:1006416410198 10.1016/0735-1097(89)90595-0 10.3904/kjim.2012.27.3.342 10.1093/annonc/mdu159 10.5694/j.1326-5377.1994.tb127388.x 10.1093/eurheartj/ehx393 10.1517/14740338.2014.954546 10.1007/s11102-015-0703-0 10.1093/annonc/mdx224 10.1373/clinchem.2005.060038 10.1136/emermed-2017-206812 10.1186/2050-6511-15-47 10.1200/JCO.1989.7.4.509 10.1001/jama.2010.1768 10.1007/s00432-007-0250-9 10.1002/jcb.27093 10.1093/annonc/mdh150 10.1093/eurheartj/ehi169 10.1093/eurheartj/ehy462 10.11613/BM.2013.021 10.1161/CIRCULATIONAHA.106.685503 |
| ContentType | Journal Article |
| Copyright | AlphaMed Press 2020 AlphaMed Press 2020. COPYRIGHT 2021 Oxford University Press |
| Copyright_xml | – notice: AlphaMed Press 2020 – notice: AlphaMed Press 2020. – notice: COPYRIGHT 2021 Oxford University Press |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1002/onco.13536 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | 5‐FU Cardiotoxicity |
| EISSN | 1549-490X |
| EndPage | e413 |
| ExternalDocumentID | PMC7930422 A780130802 32959474 10_1002_onco_13536 ONCO13536 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Denmark |
| GeographicLocations_xml | – name: Denmark |
| GrantInformation_xml | – fundername: Fonden til fremme af klinisk cancer forskning – fundername: Einar Willumsen Foundation – fundername: Højmosegaardlegatet/Lægeforeningens forskningsfond funderid: 2017‐1064/91 – fundername: Hjerteforeningen funderid: 16‐R107‐A6601‐22016 – fundername: Det Sundhedsvidenskabelige Fakultet, Københavns Universitet – fundername: Fonden af 17‐12‐1981 – fundername: Aase og Ejnar Danielsens Fond – fundername: Ingeniør August Frederik Wedell Erichsens fond funderid: Not applicable – fundername: ; – fundername: Højmosegaardlegatet/Lægeforeningens forskningsfond grantid: 2017‐1064/91 – fundername: Ingeniør August Frederik Wedell Erichsens fond grantid: Not applicable – fundername: ; grantid: 16‐R107‐A6601‐22016 |
| GroupedDBID | --- 0R~ 123 18M 1OC 24P 2WC 36B 4.4 53G 5VS AAPXW AAVAP AAWTL AAZKR ABEJV ABPTD ABXVV ACXQS ADBBV ADXAS AEGXH AENEX AJAOE ALMA_UNASSIGNED_HOLDINGS AMNDL AOIJS BAWUL BFHJK CS3 DCZOG DIK DU5 E3Z EBD EBS EJD EMB EMOBN F5P FRP GROUPED_DOAJ GX1 H13 HYE HZ~ IAO IHR INH ITC LUTES LYRES O9- OK1 P2P P2W RAO RHF RHI ROL ROX RPM SUPJJ SV3 TOX TR2 UDS W2D W8F WIN WOHZO WOQ WOW XSB ZZTAW AAFWJ AAYXX ABGNP AFPKN CITATION OVT 7X7 88E 8FI 8FJ AAMMB ABUWG AEFGJ AFKRA AGXDD AIDQK AIDYY BENPR CCPQU CGR CUY CVF ECM EIF FYUFA HMCUK M1P NPM PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO UKHRP 7X8 5PM |
| ID | FETCH-LOGICAL-c4026-3f81d110cb933d21c328f48e7f1556a595ebd40ef7f2dc52b44dc42a1e9982683 |
| ISSN | 1083-7159 1549-490X |
| IngestDate | Thu Aug 21 13:16:41 EDT 2025 Tue Aug 05 10:11:16 EDT 2025 Tue Jun 17 22:23:44 EDT 2025 Tue Jun 10 21:15:05 EDT 2025 Mon Jul 21 06:01:44 EDT 2025 Tue Jul 01 01:17:20 EDT 2025 Thu Apr 24 22:57:00 EDT 2025 Wed Jan 22 16:31:47 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Myocardial ischemia Cardiotoxicity 5-Flourouracil Anal cancer Colorectal cancer |
| Language | English |
| License | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model AlphaMed Press 2020. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c4026-3f81d110cb933d21c328f48e7f1556a595ebd40ef7f2dc52b44dc42a1e9982683 |
| Notes | Commercialreprints@wiley.com No part of this article may be reproduced, stored, or transmitted in any form or for any means without the prior permission in writing from the copyright holder. For information on purchasing reprints contact Disclosures of potential conflicts of interest may be found at the end of this article Contributed equally. For permission information contact permissions@wiley.com . ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Disclosures of potential conflicts of interest may be found at the end of this article. No part of this article may be reproduced, stored, or transmitted in any form or for any means without the prior permission in writing from the copyright holder. For information on purchasing reprints contact Commercialreprints@wiley.com. For permission information contact permissions@wiley.com. |
| ORCID | 0000-0003-2335-8219 |
| OpenAccessLink | https://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/onco.13536 |
| PMID | 32959474 |
| PQID | 2444881312 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7930422 proquest_miscellaneous_2444881312 gale_infotracmisc_A780130802 gale_infotracacademiconefile_A780130802 pubmed_primary_32959474 crossref_citationtrail_10_1002_onco_13536 crossref_primary_10_1002_onco_13536 wiley_primary_10_1002_onco_13536_ONCO13536 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | March 2021 |
| PublicationDateYYYYMMDD | 2021-03-01 |
| PublicationDate_xml | – month: 03 year: 2021 text: March 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | Hoboken, USA |
| PublicationPlace_xml | – name: Hoboken, USA – name: England |
| PublicationTitle | The oncologist (Dayton, Ohio) |
| PublicationTitleAlternate | Oncologist |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc Oxford University Press |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: Oxford University Press |
| References | 2010; 16 2017; 81 1991; 12 2013; 23 2010; 304 2002; 57 2013; 167 1994; 23 2014; 25 1988; 78 2019; 18 2018; 40 1999; 84 2005; 26 2016; 37 2005; 22 1996; 76 2018; 39 2000; 18 2010; 27 2014; 4 2013; 56 1997; 15 2004; 34 2003; 8 2014; 15 2016; 353 2003; 4 2014; 13 2007; 61 2012; 27 1994; 74 2018; 35 2007; 27 2010; 8 2017; 63 2006; 52 2016; 19 2017; 28 1989; 7 2013; 40 2008; 19 2017; 68 2007; 120 2011; 31 2020; 38 2008; 52 2014; 113 2007; 115 2004; 11 2003; 108 2011; 108 2013; 39 2018; 119 2004; 15 1994; 161 2019 2009; 8 2008; 134 2016; 27 1989; 13 1998; 5 2018; 10 2005; 12 2011; 100 Polk (2021122512040332500_onco13536-bib-0059) 2014; 15 Morgenthaler (2021122512040332500_onco13536-bib-0026) 2010; 16 Chakrabarti (2021122512040332500_onco13536-bib-0050) 2019; 18 Stagmo (2021122512040332500_onco13536-bib-0043) 2005; 12 Osterlund (2021122512040332500_onco13536-bib-0053) 2020; 38 Lestuzzi (2021122512040332500_onco13536-bib-0009) 2014; 25 Hannaford (2021122512040332500_onco13536-bib-0012) 1994; 161 Cardiology TDSo (2021122512040332500_onco13536-bib-0032) 2019 Grem (2021122512040332500_onco13536-bib-0001) 2000; 18 Nabel (2021122512040332500_onco13536-bib-0047) 1988; 78 Rotondo (2021122512040332500_onco13536-bib-0025) 2016; 19 Bjerregaard (2021122512040332500_onco13536-bib-0035) 2003; 8 Salepci (2021122512040332500_onco13536-bib-0020) 2010; 27 Ibanez (2021122512040332500_onco13536-bib-0031) 2018; 39 Orditura (2021122512040332500_onco13536-bib-0057) 1998; 5 Basselin (2021122512040332500_onco13536-bib-0037) 2011; 31 Patel (2021122512040332500_onco13536-bib-0049) 1996; 76 Roffi (2021122512040332500_onco13536-bib-0036) 2016; 37 Saif (2021122512040332500_onco13536-bib-0039) 2009; 8 (2021122512040332500_onco13536-bib-0033) 2016; 353 Cohn (2021122512040332500_onco13536-bib-0045) 2003; 108 Shoemaker (2021122512040332500_onco13536-bib-0062) 2004; 11 Kosmas (2021122512040332500_onco13536-bib-0005) 2008; 134 Polk (2021122512040332500_onco13536-bib-0006) 2013; 39 Sudhoff (2021122512040332500_onco13536-bib-0063) 2004; 15 Morgenthaler (2021122512040332500_onco13536-bib-0028) 2008; 19 Gu (2021122512040332500_onco13536-bib-0056) 2011; 100 Brygger (2021122512040332500_onco13536-bib-0058) 2014; 13 Aronow (2021122512040332500_onco13536-bib-0067) 2002; 57 Thygesen (2021122512040332500_onco13536-bib-0014) 2018; 40 Luwaert (2021122512040332500_onco13536-bib-0061) 1991; 12 Kwakman (2021122512040332500_onco13536-bib-0052) 2017; 81 de Lemos (2021122512040332500_onco13536-bib-0054) 2010; 304 Wimmer (2021122512040332500_onco13536-bib-0044) 2013; 56 Glynne-Jones (2021122512040332500_onco13536-bib-0004) 2014; 25 Parizadeh (2021122512040332500_onco13536-bib-0024) 2018; 119 de Gramont (2021122512040332500_onco13536-bib-0051) 1997; 15 Tajik (2021122512040332500_onco13536-bib-0060) 2010; 8 Fradley (2021122512040332500_onco13536-bib-0010) 2013; 40 Daniels (2021122512040332500_onco13536-bib-0055) 2008; 52 Sara (2021122512040332500_onco13536-bib-0065) 2018; 10 Sajadieh (2021122512040332500_onco13536-bib-0042) 2005; 26 Glynne-Jones (2021122512040332500_onco13536-bib-0002) 2017; 28 Ceyhan (2021122512040332500_onco13536-bib-0017) 2005; 22 Scientific (2021122512040332500_onco13536-bib-0034) Harkness (2021122512040332500_onco13536-bib-0041) 2011; 108 Body (2021122512040332500_onco13536-bib-0016) 2018; 35 Nademanee (2021122512040332500_onco13536-bib-0046) 1989; 13 Holubec (2021122512040332500_onco13536-bib-0018) 2007; 27 Nielsen (2021122512040332500_onco13536-bib-0011) 2014; 4 Khan (2021122512040332500_onco13536-bib-0030) 2007; 115 Morgenthaler (2021122512040332500_onco13536-bib-0022) 2006; 52 Mafrici (2021122512040332500_onco13536-bib-0064) 2003; 4 Dobsa (2021122512040332500_onco13536-bib-0023) 2013; 23 Kim (2021122512040332500_onco13536-bib-0038) 2012; 27 Turan (2021122512040332500_onco13536-bib-0021) 2017; 68 Forslund (2021122512040332500_onco13536-bib-0040) 1999; 84 Yalta (2021122512040332500_onco13536-bib-0027) 2013; 167 Van Cutsem (2021122512040332500_onco13536-bib-0003) 2016; 27 Yilmaz (2021122512040332500_onco13536-bib-0008) 2007; 61 Rezkalla (2021122512040332500_onco13536-bib-0007) 1989; 7 Lanza (2021122512040332500_onco13536-bib-0066) 1994; 74 Celermajer (2021122512040332500_onco13536-bib-0048) 1994; 23 Wijesinghe (2021122512040332500_onco13536-bib-0013) 2007; 120 Apple (2021122512040332500_onco13536-bib-0015) 2017; 63 Oztop (2021122512040332500_onco13536-bib-0019) 2004; 34 Lipinski (2021122512040332500_onco13536-bib-0029) 2014; 113 |
| References_xml | – volume: 22 start-page: 233 year: 2005 end-page: 238 article-title: Ultrasound tissue characterization by integrated backscatter for analyzing Fluorouracil induced myocardial damage publication-title: Echocardiography – volume: 68 start-page: 52 year: 2017 end-page: 58 article-title: Usefulness of heart‐type fatty acid‐binding protein and myocardial performance index for early detection of 5‐fluorouracil cardiotoxicity publication-title: Angiology – volume: 52 start-page: 450 year: 2008 end-page: 459 article-title: Minimally elevated cardiac troponin T and elevated N‐terminal pro‐B‐type natriuretic peptide predict mortality in older adults: Results from the Rancho Bernardo Study publication-title: J Am Coll Cardiol – volume: 25 start-page: 1059 year: 2014 end-page: 1064 article-title: Effort myocardial ischemia during chemotherapy with 5‐fluorouracil: An underestimated risk publication-title: Ann Oncol – volume: 4 start-page: 211 year: 2014 article-title: Cardiotoxicity in asymptomatic patients receiving adjuvant 5‐fluorouracil publication-title: J Clin Toxicol – volume: 13 start-page: 1407 year: 2014 end-page: 1422 article-title: 5‐Hydroxytryptamine3 receptor antagonists and cardiac side effects publication-title: Expert Opin Drug Saf – volume: 8 start-page: E111 year: 2010 end-page: E112 article-title: Angina induced by 5‐fluorouracil infusion in a patient with normal coronaries publication-title: Am Heart Hosp J – volume: 31 start-page: 226 year: 2011 article-title: 5‐Fluorouracil‐induced Tako‐Tsubo‐like syndrome publication-title: Pharmacotherapy – volume: 27 start-page: 1386 year: 2016 end-page: 1422 article-title: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer publication-title: Ann Oncol – volume: 167 start-page: 1750 year: 2013 end-page: 1759 article-title: Copeptin and cardiovascular disease: A review of a novel neurohormone publication-title: Int J Cardiol – volume: 134 start-page: 75 year: 2008 end-page: 82 article-title: Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study publication-title: J Cancer Res Clin Oncol – volume: 353 year: 2016 article-title: QT interval and drug therapy publication-title: BMJ – volume: 18 start-page: 299 year: 2000 end-page: 313 article-title: 5‐Fluorouracil: forty‐plus and still ticking. A review of its preclinical and clinical development publication-title: Invest New Drugs – volume: 26 start-page: 1402 year: 2005 end-page: 1409 article-title: Prevalence and prognostic significance of daily‐life silent myocardial ischaemia in middle‐aged and elderly subjects with no apparent heart disease publication-title: Eur Heart J – volume: 8 start-page: 200 year: 2003 end-page: 207 article-title: ST segment analysis by Holter Monitoring: Methodological considerations publication-title: Ann Noninvasive Electrocardiol – volume: 39 start-page: 974 year: 2013 end-page: 984 article-title: Cardiotoxicity in cancer patients treated with 5‐fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors publication-title: Cancer Treat Rev – volume: 27 start-page: 342 year: 2012 end-page: 345 article-title: A case of severe coronary spasm associated with 5‐fluorouracil chemotherapy publication-title: Korean J Intern Med – volume: 5 start-page: 645 year: 1998 end-page: 647 article-title: Analysis of recovery time indexes in 5‐fluorouracil‐treated cancer patients publication-title: Oncol. Rep – volume: 52 start-page: 112 year: 2006 end-page: 119 article-title: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin publication-title: Clin Chem – volume: 108 start-page: 1263 year: 2003 end-page: 1277 article-title: Silent myocardial ischemia publication-title: Circulation – volume: 56 start-page: 195 year: 2013 end-page: 202 article-title: The clinical significance of continuous ECG (ambulatory ECG or Holter) monitoring of the ST‐segment to evaluate ischemia: A review publication-title: Prog Cardiovasc Dis – volume: 37 start-page: 267 year: 2016 end-page: 315 article-title: 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‐segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST‐Segment Elevation of the European Society of Cardiology (ESC) publication-title: Eur Heart J – volume: 57 start-page: M178 year: 2002 end-page: 180 article-title: Prevalence and association of ventricular tachycardia and complex ventricular arrhythmias with new coronary events in older men and women with and without cardiovascular disease publication-title: J Gerontol A Biol Sci Med Sci – volume: 4 start-page: 895 year: 2003 end-page: 899 article-title: Management of patients with persistent chest pain and ST‐segment elevation during 5‐fluorouracil treatment: report about two cases publication-title: Ital Heart J – volume: 40 start-page: 237 year: 2018 end-page: 269 article-title: Fourth universal definition of myocardial infarction (2018) publication-title: Eur Heart J – volume: 27 start-page: 1883 year: 2007 end-page: 1886 article-title: Dynamic monitoring of cardio‐specific markers and markers of thyroid gland function in cancer patients–a pilot study publication-title: Anticancer Res – volume: 35 start-page: 120 year: 2018 end-page: 125 article-title: Understanding cardiac troponin part 1: Avoiding troponinitis publication-title: Emerg Med J – volume: 76 start-page: 477 year: 1996 end-page: 482 article-title: Natural variability of transient myocardial ischaemia during daily life: An obstacle when assessing efficacy of anti‐ischaemic agents? publication-title: Heart – volume: 40 start-page: 472 year: 2013 end-page: 476 article-title: Ventricular fibrillation cardiac arrest due to 5‐fluorouracil cardiotoxicity publication-title: Tex Heart Inst J – volume: 23 start-page: 66 year: 1994 end-page: 73 article-title: Variability of episodic ST segment depression in chronic stable angina: Implications for individual and group trials of therapeutic efficacy publication-title: J Am Coll Cardiol – volume: 28 start-page: iv22 year: 2017 end-page: iv40 article-title: Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up publication-title: Ann Oncol – year: 2019 – volume: 61 start-page: 795 year: 2007 end-page: 801 article-title: 5‐fluorouracil increases the number and complexity of premature complexes in the heart: A prospective study using ambulatory ECG monitoring publication-title: Int J Clin Pract – volume: 63 start-page: 73 year: 2017 end-page: 81 article-title: Cardiac troponin assays: Guide to understanding analytical characteristics and their impact on clinical care publication-title: Clin Chem – volume: 81 start-page: 130 year: 2017 end-page: 134 article-title: Case series of patients treated with the oral fluoropyrimidine S‐1 after capecitabine‐induced coronary artery vasospasm publication-title: Eur J Cancer – volume: 13 start-page: 574 year: 1989 end-page: 579 article-title: Variability of indexes for myocardial ischemia: A comparison of exercise treadmill test, ambulatory electrocardiographic monitoring and symptoms of myocardial ischemia publication-title: J Am Coll Cardiol – volume: 7 start-page: 509 year: 1989 end-page: 514 article-title: Continuous ambulatory ECG monitoring during fluorouracil therapy: A prospective study publication-title: J Clin Oncol – volume: 100 start-page: 1069 year: 2011 end-page: 1076 article-title: Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction publication-title: Clin Res Cardiol – volume: 15 start-page: 808 year: 1997 end-page: 815 article-title: Randomized trial comparing monthly low‐dose leucovorin and fluorouracil bolus with bimonthly high‐dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study publication-title: J Clin Oncol – volume: 108 start-page: 1373 year: 2011 end-page: 1381 article-title: Myocardial ischemia and ventricular tachycardia on continuous electrocardiographic monitoring and risk of cardiovascular outcomes after non‐ST‐segment elevation acute coronary syndrome (from the MERLIN‐TIMI 36 Trial) publication-title: Am J Cardiol – volume: 12 start-page: 468 year: 1991 end-page: 470 article-title: Coronary artery spasm induced by 5‐fluorouracil publication-title: Eur Heart J – volume: 27 start-page: 416 year: 2010 end-page: 420 article-title: 5‐Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels publication-title: Med Oncol – volume: 15 year: 2014 article-title: A systematic review of the pathophysiology of 5‐fluorouracil‐induced cardiotoxicity publication-title: BMC Pharmacol Toxicol – volume: 10 year: 2018 article-title: 5‐fluorouracil and cardiotoxicity: A review publication-title: Ther Adv Med Oncol – volume: 23 start-page: 172 year: 2013 end-page: 190 article-title: Copeptin and its potential role in diagnosis and prognosis of various diseases publication-title: Biochem Med (Zagreb) – volume: 8 start-page: 191 year: 2009 end-page: 202 article-title: Fluoropyrimidine‐associated cardiotoxicity: Revisited publication-title: Expert Opin Drug Saf – volume: 34 start-page: 262 year: 2004 end-page: 268 article-title: Evaluation of cardiotoxicity of a combined bolus plus infusional 5‐fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers publication-title: Jpn J Clin Oncol – volume: 78 start-page: 60 year: 1988 end-page: 67 article-title: Variability of transient myocardial ischemia in ambulatory patients with coronary artery disease publication-title: Circulation – volume: 120 start-page: U2836 year: 2007 article-title: A case of late‐onset severe cardiotoxicity from 5‐fluorouracil therapy resulting in death publication-title: N Z Med J – volume: 39 start-page: 119 year: 2018 end-page: 177 article-title: 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST‐segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST‐segment elevation of the European Society of Cardiology (ESC) publication-title: Eur Heart J – volume: 84 start-page: 1151 year: 1999 end-page: 1157 article-title: Prognostic implications of ambulatory myocardial ischemia and arrhythmias and relations to ischemia on exercise in chronic stable angina pectoris (the Angina Prognosis Study in Stockholm [APSIS]) publication-title: Am J Cardiol – volume: 119 start-page: 7913 year: 2018 end-page: 7923 article-title: The diagnostic and prognostic value of copeptin in cardiovascular disease, current status, and prospective publication-title: J Cell Biochem – volume: 18 start-page: 52 year: 2019 end-page: 57 article-title: Bolus 5‐fluorouracil (5‐FU) in combination with oxaliplatin is safe and well tolerated in patients who experienced coronary vasospasm with infusional 5‐FU or capecitabine publication-title: Clin Colorectal Cancer – volume: 38 start-page: 7037a issue: suppl 15 year: 2020 article-title: Feasibility of switching to S‐1 after other fluoropyrimidine‐related cardiotoxicity during chemotherapy for solid tumors publication-title: J Clin Oncol – volume: 115 start-page: 2103 year: 2007 end-page: 2110 article-title: C‐terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study publication-title: Circulation – volume: 11 start-page: 46 year: 2004 end-page: 49 article-title: 5‐fluorouracil‐induced coronary vasospasm publication-title: Cancer Control – volume: 74 start-page: 1216 year: 1994 end-page: 1219 article-title: Usefulness of a third Holter lead for detection of myocardial ischemia publication-title: Am J Cardiol – volume: 19 start-page: 43 year: 2008 end-page: 49 article-title: Copeptin: Clinical use of a new biomarker publication-title: Trends Endocrinol Metab – volume: 113 start-page: 1581 year: 2014 end-page: 1591 article-title: A systematic review and collaborative meta‐analysis to determine the incremental value of copeptin for rapid rule‐out of acute myocardial infarction publication-title: Am J Cardiol – volume: 19 start-page: 345 year: 2016 end-page: 355 article-title: Arginine vasopressin (AVP): A review of its historical perspectives, current research and multifunctional role in the hypothalamo‐hypophysial system publication-title: Pituitary – volume: 15 start-page: 661 year: 2004 end-page: 664 article-title: 5‐Fluorouracil induces arterial vasocontractions publication-title: Ann Oncol – volume: 25 start-page: iii10 issue: suppl 3 year: 2014 end-page: iii20 article-title: Anal cancer: ESMO‐ESSO‐ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow‐up publication-title: Ann Oncol – volume: 161 start-page: 225 year: 1994 article-title: Sudden death associated with 5‐fluorouracil publication-title: Med J Aust – volume: 12 start-page: 478 year: 2005 end-page: 483 article-title: Fifteen‐year risk of major coronary events predicted by Holter ST‐monitoring in asymptomatic middle‐aged men publication-title: Eur J Cardiovasc Prev Rehabil – volume: 16 start-page: S37 issue: suppl 1 year: 2010 end-page: S44 article-title: Copeptin: A biomarker of cardiovascular and renal function publication-title: Congest Heart Fail – volume: 304 start-page: 2503 year: 2010 end-page: 2512 article-title: Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population publication-title: JAMA – volume: 78 start-page: 60 year: 1988 ident: 2021122512040332500_onco13536-bib-0047 article-title: Variability of transient myocardial ischemia in ambulatory patients with coronary artery disease publication-title: Circulation doi: 10.1161/01.CIR.78.1.60 – volume: 167 start-page: 1750 year: 2013 ident: 2021122512040332500_onco13536-bib-0027 article-title: Copeptin and cardiovascular disease: A review of a novel neurohormone publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2012.12.039 – volume: 108 start-page: 1373 year: 2011 ident: 2021122512040332500_onco13536-bib-0041 article-title: Myocardial ischemia and ventricular tachycardia on continuous electrocardiographic monitoring and risk of cardiovascular outcomes after non-ST-segment elevation acute coronary syndrome (from the MERLIN-TIMI 36 Trial) publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2011.06.058 – volume: 4 start-page: 895 year: 2003 ident: 2021122512040332500_onco13536-bib-0064 article-title: Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases publication-title: Ital Heart J – volume: 84 start-page: 1151 year: 1999 ident: 2021122512040332500_onco13536-bib-0040 article-title: Prognostic implications of ambulatory myocardial ischemia and arrhythmias and relations to ischemia on exercise in chronic stable angina pectoris (the Angina Prognosis Study in Stockholm [APSIS]) publication-title: Am J Cardiol doi: 10.1016/S0002-9149(99)00526-3 – volume: 108 start-page: 1263 year: 2003 ident: 2021122512040332500_onco13536-bib-0045 article-title: Silent myocardial ischemia publication-title: Circulation doi: 10.1161/01.CIR.0000088001.59265.EE – volume: 8 start-page: E111 year: 2010 ident: 2021122512040332500_onco13536-bib-0060 article-title: Angina induced by 5-fluorouracil infusion in a patient with normal coronaries publication-title: Am Heart Hosp J doi: 10.15420/ahhj.2010.8.2.111 – volume: 25 start-page: 1059 year: 2014 ident: 2021122512040332500_onco13536-bib-0009 article-title: Effort myocardial ischemia during chemotherapy with 5-fluorouracil: An underestimated risk publication-title: Ann Oncol doi: 10.1093/annonc/mdu055 – volume: 27 start-page: 1386 year: 2016 ident: 2021122512040332500_onco13536-bib-0003 article-title: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdw235 – volume: 18 start-page: 52 year: 2019 ident: 2021122512040332500_onco13536-bib-0050 article-title: Bolus 5-fluorouracil (5-FU) in combination with oxaliplatin is safe and well tolerated in patients who experienced coronary vasospasm with infusional 5-FU or capecitabine publication-title: Clin Colorectal Cancer doi: 10.1016/j.clcc.2018.09.006 – volume: 22 start-page: 233 year: 2005 ident: 2021122512040332500_onco13536-bib-0017 article-title: Ultrasound tissue characterization by integrated backscatter for analyzing Fluorouracil induced myocardial damage publication-title: Echocardiography doi: 10.1111/j.0742-2822.2005.03169.x – volume: 8 start-page: 191 year: 2009 ident: 2021122512040332500_onco13536-bib-0039 article-title: Fluoropyrimidine-associated cardiotoxicity: Revisited publication-title: Expert Opin Drug Saf doi: 10.1517/14740330902733961 – volume: 23 start-page: 66 year: 1994 ident: 2021122512040332500_onco13536-bib-0048 article-title: Variability of episodic ST segment depression in chronic stable angina: Implications for individual and group trials of therapeutic efficacy publication-title: J Am Coll Cardiol doi: 10.1016/0735-1097(94)90503-7 – volume: 100 start-page: 1069 year: 2011 ident: 2021122512040332500_onco13536-bib-0056 article-title: Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction publication-title: Clin Res Cardiol doi: 10.1007/s00392-011-0343-y – volume: 11 start-page: 46 year: 2004 ident: 2021122512040332500_onco13536-bib-0062 article-title: 5-fluorouracil-induced coronary vasospasm publication-title: Cancer Control doi: 10.1177/107327480401100107 – volume: 63 start-page: 73 year: 2017 ident: 2021122512040332500_onco13536-bib-0015 article-title: Cardiac troponin assays: Guide to understanding analytical characteristics and their impact on clinical care publication-title: Clin Chem doi: 10.1373/clinchem.2016.255109 – volume: 34 start-page: 262 year: 2004 ident: 2021122512040332500_onco13536-bib-0019 article-title: Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers publication-title: Jpn J Clin Oncol doi: 10.1093/jjco/hyh047 – volume: 4 start-page: 211 year: 2014 ident: 2021122512040332500_onco13536-bib-0011 article-title: Cardiotoxicity in asymptomatic patients receiving adjuvant 5-fluorouracil publication-title: J Clin Toxicol doi: 10.4172/2161-0495.1000211 – volume: 19 start-page: 43 year: 2008 ident: 2021122512040332500_onco13536-bib-0028 article-title: Copeptin: Clinical use of a new biomarker publication-title: Trends Endocrinol Metab doi: 10.1016/j.tem.2007.11.001 – volume: 37 start-page: 267 year: 2016 ident: 2021122512040332500_onco13536-bib-0036 article-title: 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) publication-title: Eur Heart J doi: 10.1093/eurheartj/ehv320 – volume: 5 start-page: 645 year: 1998 ident: 2021122512040332500_onco13536-bib-0057 article-title: Analysis of recovery time indexes in 5-fluorouracil-treated cancer patients publication-title: Oncol. Rep – volume: 52 start-page: 450 year: 2008 ident: 2021122512040332500_onco13536-bib-0055 article-title: Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: Results from the Rancho Bernardo Study publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2008.04.033 – volume: 38 start-page: 7037a issue: suppl 15 year: 2020 ident: 2021122512040332500_onco13536-bib-0053 article-title: Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors publication-title: J Clin Oncol doi: 10.1200/JCO.2020.38.15_suppl.7037 – volume: 31 start-page: 226 year: 2011 ident: 2021122512040332500_onco13536-bib-0037 article-title: 5-Fluorouracil-induced Tako-Tsubo-like syndrome publication-title: Pharmacotherapy doi: 10.1592/phco.31.2.226 – volume: 68 start-page: 52 year: 2017 ident: 2021122512040332500_onco13536-bib-0021 article-title: Usefulness of heart-type fatty acid-binding protein and myocardial performance index for early detection of 5-fluorouracil cardiotoxicity publication-title: Angiology doi: 10.1177/0003319716637516 – volume: 76 start-page: 477 year: 1996 ident: 2021122512040332500_onco13536-bib-0049 article-title: Natural variability of transient myocardial ischaemia during daily life: An obstacle when assessing efficacy of anti-ischaemic agents? publication-title: Heart doi: 10.1136/hrt.76.6.477 – volume: 61 start-page: 795 year: 2007 ident: 2021122512040332500_onco13536-bib-0008 article-title: 5-fluorouracil increases the number and complexity of premature complexes in the heart: A prospective study using ambulatory ECG monitoring publication-title: Int J Clin Pract doi: 10.1111/j.1742-1241.2007.01323.x – volume: 39 start-page: 974 year: 2013 ident: 2021122512040332500_onco13536-bib-0006 article-title: Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2013.03.005 – volume: 16 start-page: S37 issue: suppl 1 year: 2010 ident: 2021122512040332500_onco13536-bib-0026 article-title: Copeptin: A biomarker of cardiovascular and renal function publication-title: Congest Heart Fail doi: 10.1111/j.1751-7133.2010.00177.x – volume: 353 start-page: i2732 year: 2016 ident: 2021122512040332500_onco13536-bib-0033 article-title: QT interval and drug therapy publication-title: BMJ – volume: 74 start-page: 1216 year: 1994 ident: 2021122512040332500_onco13536-bib-0066 article-title: Usefulness of a third Holter lead for detection of myocardial ischemia publication-title: Am J Cardiol doi: 10.1016/0002-9149(94)90551-7 – volume: 12 start-page: 468 year: 1991 ident: 2021122512040332500_onco13536-bib-0061 article-title: Coronary artery spasm induced by 5-fluorouracil publication-title: Eur Heart J doi: 10.1093/oxfordjournals.eurheartj.a059919 – volume: 8 start-page: 200 year: 2003 ident: 2021122512040332500_onco13536-bib-0035 article-title: ST segment analysis by Holter Monitoring: Methodological considerations publication-title: Ann Noninvasive Electrocardiol doi: 10.1046/j.1542-474X.2003.08306.x – volume: 12 start-page: 478 year: 2005 ident: 2021122512040332500_onco13536-bib-0043 article-title: Fifteen-year risk of major coronary events predicted by Holter ST-monitoring in asymptomatic middle-aged men publication-title: Eur J Cardiovasc Prev Rehabil doi: 10.1097/01.hjr.0000176511.22284.c1 – volume-title: Guidelines from The Danish Society of Cardiology: Acute coronary syndromes year: 2019 ident: 2021122512040332500_onco13536-bib-0032 – volume: 56 start-page: 195 year: 2013 ident: 2021122512040332500_onco13536-bib-0044 article-title: The clinical significance of continuous ECG (ambulatory ECG or Holter) monitoring of the ST-segment to evaluate ischemia: A review publication-title: Prog Cardiovasc Dis doi: 10.1016/j.pcad.2013.07.001 – volume: 10 start-page: 1758835918780140 year: 2018 ident: 2021122512040332500_onco13536-bib-0065 article-title: 5-fluorouracil and cardiotoxicity: A review publication-title: Ther Adv Med Oncol doi: 10.1177/1758835918780140 – volume: 15 start-page: 808 year: 1997 ident: 2021122512040332500_onco13536-bib-0051 article-title: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study publication-title: J Clin Oncol doi: 10.1200/JCO.1997.15.2.808 – volume: 27 start-page: 416 year: 2010 ident: 2021122512040332500_onco13536-bib-0020 article-title: 5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels publication-title: Med Oncol doi: 10.1007/s12032-009-9226-8 – volume: 113 start-page: 1581 year: 2014 ident: 2021122512040332500_onco13536-bib-0029 article-title: A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2014.01.436 – volume: 57 start-page: M178 year: 2002 ident: 2021122512040332500_onco13536-bib-0067 article-title: Prevalence and association of ventricular tachycardia and complex ventricular arrhythmias with new coronary events in older men and women with and without cardiovascular disease publication-title: J Gerontol A Biol Sci Med Sci doi: 10.1093/gerona/57.3.M178 – volume: 81 start-page: 130 year: 2017 ident: 2021122512040332500_onco13536-bib-0052 article-title: Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm publication-title: Eur J Cancer doi: 10.1016/j.ejca.2017.05.022 – volume: 18 start-page: 299 year: 2000 ident: 2021122512040332500_onco13536-bib-0001 article-title: 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development publication-title: Invest New Drugs doi: 10.1023/A:1006416410198 – volume: 120 start-page: U2836 year: 2007 ident: 2021122512040332500_onco13536-bib-0013 article-title: A case of late-onset severe cardiotoxicity from 5-fluorouracil therapy resulting in death publication-title: N Z Med J – volume: 13 start-page: 574 year: 1989 ident: 2021122512040332500_onco13536-bib-0046 article-title: Variability of indexes for myocardial ischemia: A comparison of exercise treadmill test, ambulatory electrocardiographic monitoring and symptoms of myocardial ischemia publication-title: J Am Coll Cardiol doi: 10.1016/0735-1097(89)90595-0 – volume: 27 start-page: 342 year: 2012 ident: 2021122512040332500_onco13536-bib-0038 article-title: A case of severe coronary spasm associated with 5-fluorouracil chemotherapy publication-title: Korean J Intern Med doi: 10.3904/kjim.2012.27.3.342 – volume: 25 start-page: iii10 issue: suppl 3 year: 2014 ident: 2021122512040332500_onco13536-bib-0004 article-title: Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol doi: 10.1093/annonc/mdu159 – volume: 161 start-page: 225 year: 1994 ident: 2021122512040332500_onco13536-bib-0012 article-title: Sudden death associated with 5-fluorouracil publication-title: Med J Aust doi: 10.5694/j.1326-5377.1994.tb127388.x – volume-title: Product Specifications: Thermo Scientific BRAMS Copeptin proAVP ident: 2021122512040332500_onco13536-bib-0034 – volume: 39 start-page: 119 year: 2018 ident: 2021122512040332500_onco13536-bib-0031 article-title: 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) publication-title: Eur Heart J doi: 10.1093/eurheartj/ehx393 – volume: 13 start-page: 1407 year: 2014 ident: 2021122512040332500_onco13536-bib-0058 article-title: 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects publication-title: Expert Opin Drug Saf doi: 10.1517/14740338.2014.954546 – volume: 19 start-page: 345 year: 2016 ident: 2021122512040332500_onco13536-bib-0025 article-title: Arginine vasopressin (AVP): A review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system publication-title: Pituitary doi: 10.1007/s11102-015-0703-0 – volume: 28 start-page: iv22 year: 2017 ident: 2021122512040332500_onco13536-bib-0002 article-title: Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol doi: 10.1093/annonc/mdx224 – volume: 52 start-page: 112 year: 2006 ident: 2021122512040332500_onco13536-bib-0022 article-title: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin publication-title: Clin Chem doi: 10.1373/clinchem.2005.060038 – volume: 35 start-page: 120 year: 2018 ident: 2021122512040332500_onco13536-bib-0016 article-title: Understanding cardiac troponin part 1: Avoiding troponinitis publication-title: Emerg Med J doi: 10.1136/emermed-2017-206812 – volume: 15 start-page: 47 year: 2014 ident: 2021122512040332500_onco13536-bib-0059 article-title: A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity publication-title: BMC Pharmacol Toxicol doi: 10.1186/2050-6511-15-47 – volume: 7 start-page: 509 year: 1989 ident: 2021122512040332500_onco13536-bib-0007 article-title: Continuous ambulatory ECG monitoring during fluorouracil therapy: A prospective study publication-title: J Clin Oncol doi: 10.1200/JCO.1989.7.4.509 – volume: 304 start-page: 2503 year: 2010 ident: 2021122512040332500_onco13536-bib-0054 article-title: Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population publication-title: JAMA doi: 10.1001/jama.2010.1768 – volume: 134 start-page: 75 year: 2008 ident: 2021122512040332500_onco13536-bib-0005 article-title: Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-007-0250-9 – volume: 119 start-page: 7913 year: 2018 ident: 2021122512040332500_onco13536-bib-0024 article-title: The diagnostic and prognostic value of copeptin in cardiovascular disease, current status, and prospective publication-title: J Cell Biochem doi: 10.1002/jcb.27093 – volume: 40 start-page: 472 year: 2013 ident: 2021122512040332500_onco13536-bib-0010 article-title: Ventricular fibrillation cardiac arrest due to 5-fluorouracil cardiotoxicity publication-title: Tex Heart Inst J – volume: 15 start-page: 661 year: 2004 ident: 2021122512040332500_onco13536-bib-0063 article-title: 5-Fluorouracil induces arterial vasocontractions publication-title: Ann Oncol doi: 10.1093/annonc/mdh150 – volume: 26 start-page: 1402 year: 2005 ident: 2021122512040332500_onco13536-bib-0042 article-title: Prevalence and prognostic significance of daily-life silent myocardial ischaemia in middle-aged and elderly subjects with no apparent heart disease publication-title: Eur Heart J doi: 10.1093/eurheartj/ehi169 – volume: 40 start-page: 237 year: 2018 ident: 2021122512040332500_onco13536-bib-0014 article-title: Fourth universal definition of myocardial infarction (2018) publication-title: Eur Heart J doi: 10.1093/eurheartj/ehy462 – volume: 23 start-page: 172 year: 2013 ident: 2021122512040332500_onco13536-bib-0023 article-title: Copeptin and its potential role in diagnosis and prognosis of various diseases publication-title: Biochem Med (Zagreb) doi: 10.11613/BM.2013.021 – volume: 115 start-page: 2103 year: 2007 ident: 2021122512040332500_onco13536-bib-0030 article-title: C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.106.685503 – volume: 27 start-page: 1883 year: 2007 ident: 2021122512040332500_onco13536-bib-0018 article-title: Dynamic monitoring of cardio-specific markers and markers of thyroid gland function in cancer patients–a pilot study publication-title: Anticancer Res |
| SSID | ssj0015932 |
| Score | 2.4103715 |
| Snippet | Background
Cardiotoxicity induced by 5‐fluorouracil (5‐FU) is well known but poorly understood. In this study, we undertook ECG recording (Holter) and analyses... Cardiotoxicity induced by 5-fluorouracil (5-FU) is well known but poorly understood. In this study, we undertook ECG recording (Holter) and analyses of the... Background. Cardiotoxicity induced by 5-fluorouracil (5-FU) is well known but poorly understood. In this study, we undertook ECG recording (Holter) and... Subjects, Materials, and Methods. Patients with colorectal or anal cancer that received first-time treatment with 5-FUbased chemotherapy were prospectively... Cardiotoxicity related to 5‐fluorouracil (5‐FU) treatment is poorly understood. This article reports results of a study using electrocardiogram results to... |
| SourceID | pubmedcentral proquest gale pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e403 |
| SubjectTerms | 5‐Flourouracil Anal cancer Analysis Antimitotic agents Antineoplastic agents Biomarkers Cancer Cardiac patients Cardiotoxicity Care and treatment Chemotherapy Colorectal cancer Complications and side effects Coronary heart disease Diagnosis Dosage and administration Drug therapy Electrocardiogram Electrocardiography Ethylenediaminetetraacetic acid Fluorouracil Fluorouracil - adverse effects Gastrointestinal Cancer Humans Myocardial ischemia Myocardial Ischemia - chemically induced Prospective Studies Risk factors |
| Title | Myocardial Ischemia Induced by 5‐Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fonco.13536 https://www.ncbi.nlm.nih.gov/pubmed/32959474 https://www.proquest.com/docview/2444881312 https://pubmed.ncbi.nlm.nih.gov/PMC7930422 |
| Volume | 26 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1549-490X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0015932 issn: 1083-7159 databaseCode: DIK dateStart: 19960101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1549-490X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0015932 issn: 1083-7159 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1549-490X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0015932 issn: 1083-7159 databaseCode: RPM dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVASL databaseName: Open Access: Oxford University Press Open Journals customDbUrl: eissn: 1549-490X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0015932 issn: 1083-7159 databaseCode: TOX dateStart: 19960101 isFulltext: true titleUrlDefault: https://academic.oup.com/journals/ providerName: Oxford University Press |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELaqISFeEL8pDGQEEoIp0NhOnPA2dZsGqOskOtS3KHEctaJNUGkfyr_AP82d7aZJqSbgJYpi6-Tkvth39t13hLyKtOR-kEdeCD08IXPpZZmvPJ318rjohUxkmCg8uAjPr8SncTDudH41opZWy-yd-rk3r-R_tArPQK-YJfsPmq2FwgO4B_3CFTQM17_S8WANK9HCpH58BC9Vz6fpEdbiUNasDLyz2apagKRUTWc2B_1yUW2SK49ObQkcI8IyVzvy1r4RqrBQ5RzDdxYm3LB1AIzwqkpDeQ1AQTv1JF27UPzhZFo1dhhO1pOZd1nNvtkAyu05PjKArsyOLEb81ij9itOO2xj6PAXrVJeNzVjMXXSNKMv7UsGwdXPzgjWit65LimzMx2AhetJ3pOFuwrYp9g6YvDH7amH4Ev5cFizNLH4VU-djh3vb0v_KCA9xIyQmvcFkGGI5jNFwXB9JBTG3R-duRDXXLXu_FdyybnbX-IaRsxuA23SMjGUzukNuO5eEHlt83SUdXd4jNwcu6OI-mW9hRjcwow5mNFvTNsw-0GPaABndBzIKIKMOZLQGGTUge0Cuzk5H_XPPVenwlAAH3uMFuDxgRKos5jxnvuIsKgTMAQWYqmEaxIHOctHThSxYrgKWCZErwVJfg6fPwog_JAdlVerHhJq6WUUYMyaxJHoQRTyXObohGfJlhl3yZvN1E-Uo7LGSyiyx5NssQU0kRhNd8rLu-90St-zt9RqVlCBaQJJKXVIKjAd50ZItKrrksNUTZmHVan6xUXOCTRi6WOpq9SMB-xkWSZ_70OeRVXs9IM7iIBZSdIlsAaLugOTv7ZZyOjEk8LCuIn1fl7w10LnmHZPhRX9o7p5c_w5Pya3tP3pIDpaLlX4GJvcye25-hd-kEtmI |
| linkProvider | Oxford University Press |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Myocardial+Ischemia+Induced+by+5-Fluorouracil%3A+A+Prospective+Electrocardiographic+and+Cardiac+Biomarker+Study&rft.jtitle=The+oncologist+%28Dayton%2C+Ohio%29&rft.au=Dyhl-Polk%2C+Anne&rft.au=Schou%2C+Morten&rft.au=Vistisen%2C+Kirsten+K&rft.au=Sillesen%2C+Anne-Sophie&rft.date=2021-03-01&rft.pub=Oxford+University+Press&rft.issn=1083-7159&rft.volume=26&rft.issue=3&rft.spage=e403&rft_id=info:doi/10.1002%2Fonco.13536&rft.externalDocID=A780130802 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1083-7159&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1083-7159&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1083-7159&client=summon |